Skip to main content
Home / The International Journal of Tuberculosis and Lung Disease, Volume 17, Number 11

Contribution of CD14-159C/T polymorphism to tuberculosis susceptibility: a meta-analysis

Buy Article:

$34.78 + tax (Refund Policy)

BACKGROUND: CD14 plays an important role in recognising the tuberculosis (TB) antigen and initiating immune response. CD14-159C/T polymorphism has been reported to be associated with susceptibility to TB in some, but not all studies.

OBJECTIVE: To comprehensively evaluate the correlation between CD14-159C/T polymorphism and susceptibility to TB.

METHODS: Relevant studies from six English-language databases were searched up to 15 March 2013. Crude odd ratios (ORs) with 95% confidence interval (CIs) were calculated to assess the strength of associations.

RESULTS: Eight eligible studies including 3583 subjects were retained for the meta-analysis. T-allele and TT homozygosis might increase TB risk in the overall analysis (T vs. C: OR 1.30, 95%CI 1.03–1.64, P = 0.03 and TT vs. CC+CT: OR 1.52, 95%CI 1.12–2.08, P = 0.01). Similar correlations were observed among human immunodeficiency virus negative subjects. Strong associations were also found between CD14-159C/T and TB in Asians. Asian individuals with the T-allele and the TT genotype had a significantly increased risk of TB (T vs. C: OR 1.46, 95%CI 1.27–1.68, P = 0.00; TT vs. CC: OR 1.83, 95%CI 1.38–2.44, P = 0.00 and TT vs. CC+CT: OR 1.84, 95%CI 1.55–2.19, P = 0.00). No associations were detected in the pulmonary TB and extra-pulmonary TB groups.

CONCLUSION: CD14-159C/T contributes to TB susceptibility; the T-allele and TT homozygosis are potential risk factors, particularly in Asians.

Keywords: Hardy-Weinberg equilibrium; genome-wide association study; innate immunity; single nucleotide polymorphism

Document Type: Research Article

Affiliations: 1: Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China 2: School of Pharmacy, Shanghai Jiaotong University, Shanghai, China; Shanghai Laiyi Center for Biopharmaceutical R&D, Shanghai, China 3: Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China; Shanghai Laiyi Center for Biopharmaceutical R&D, Shanghai, China 4: Shanghai Laiyi Center for Biopharmaceutical R&D, Shanghai, China 5: Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China; and Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA

Publication date: 01 November 2013

More about this publication?

  • The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.

    The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content